1/24/2006 2:11:57 PM
(January 23, 2006) – The Theramed Corporation (“Theramed” or the “Company”) announced today that it has entered into a License and Distribution Agreement with Nature’s Plus, a division of EMS Sigma Pharma for the Sigmasporin® (cyclosporine) product line. EMS Sigma Pharma is the second largest locally-owned Brazilian pharmaceutical company with over $600 million in annual sales and a rapidly expanding European operation. Bourne Partners served as Theramed’s exclusive financial advisor in this transaction.
Theramed will seek approval to market Sigmasporin® as a prophylactic against organ rejection in kidney, liver, and heart allogeneic transplants, as a potential treatment for patients with severe active rheumatoid arthritis, and in the treatment of adult nonimmunocompromised patients with severe, recalcitrant, plaque psoriasis. Sigmasporin® is bioequivalent Canada’s leading cyclosporine product, Neoral®, which is marketed by Novartis Pharmaceuticals Canada, Inc. According to IMS Health data for the Canadian market, Neoral® sales in 2004 were estimated at approximately C$40 million. In the United States, sales of all cyclosporine products were in excess of $235 million in 2004.
Theramed plans to market Sigmasporin® in 25mg, 50mg and 100mg strengths...More.
comments powered by